Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-28,800
Closed -$1.59M 155
2026
Q1
$1.59M Buy
+28,800
New +$1.56M 0.25% 85
2025
Q4
Sell
-13,360
Closed -$577K 142
2025
Q3
$577K Buy
+13,360
New +$522K 0.08% 160
2025
Q2
Sell
-13,360
Closed -$506K 218
2025
Q1
$506K Hold
13,360
0.08% 155
2024
Q4
$452K Hold
13,360
0.07% 173
2024
Q3
$546K Hold
13,360
0.09% 145
2024
Q2
$514K Hold
13,360
0.08% 153
2024
Q1
$573K Buy
13,360
+560
+4% +$23.1K 0.11% 143
2023
Q4
$505K Sell
12,800
-560
-4% -$20.1K 0.25% 107
2023
Q3
$481K Hold
13,360
0.1% 157
2023
Q2
$472K Buy
+13,360
New +$479K 0.1% 142
2021
Q2
Sell
-16,560
Closed -$739K 323
2021
Q1
$739K Sell
16,560
-12,240
-43% -$556K 0.16% 113
2020
Q4
$1.34M Hold
28,800
0.3% 65
2020
Q3
$1.35M Buy
28,800
+12,800
+80% +$641K 0.37% 60
2020
Q2
$816K Buy
+16,000
New +$821K 0.4% 33
2020
Q1
Sell
-4,000
Closed -$235K 213
2019
Q4
$235K Hold
4,000
0.05% 248
2019
Q3
$204K Hold
4,000
0.05% 256
2019
Q2
$201K Buy
+4,000
New +$201K 0.05% 253
2016
Q2
Sell
-21,645
Closed -$1.1M 274
2016
Q1
$1.1M Buy
+21,645
New +$1.08M 0.19% 108

Other funds holding GSK

Sanders Morris Harris's GSK Position: Q2 2026 in Review

Sanders Morris Harris sold out of GSK (GSK) in Q2 2026, closing a stake of 28,800 shares — an estimated $1.59M sold.

Sanders Morris Harris first reported a position in GSK in Q1 2016 and held it in 18 quarters. The position peaked at $1.59M in Q1 2026. 161 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Sanders Morris Harris reported no remaining GSK position as of Q2 2026 after selling out during the quarter.
  • Sanders Morris Harris sold 28,800 GSK shares in Q2 2026, an estimated $1.59M.
  • Sanders Morris Harris first reported a position in GSK in Q1 2016 and held it in 18 quarters.
  • Sanders Morris Harris's GSK position peaked at $1.59M in Q1 2026.
  • 161 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Sanders Morris Harris's 13F filing for Q2 2026, filed 7 Jul 2026.